Shopping Cart
- Remove All
- Your shopping cart is currently empty
Cyclo(RGDfC) TFA (Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA) is a cyclic pentapeptide, a cyclic RGD polypeptide with high affinity for αvβ3, which is capable of disrupting cellular integrin interactions. Cyclo(RGDfC) TFA inhibits pluripotent gene expression in embryonic stem cells (ESCs) and inhibits tumorigenic potential of mESCs in vivo. Cyclo(RGDfC) TFA inhibits the tumorigenic potential of mESC. Cyclo(RGDfC) TFA can be used for tumor-related studies.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $38 | Backorder | |
5 mg | Inquiry | In Stock |
Description | Cyclo(RGDfC) TFA (Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA) is a cyclic pentapeptide, a cyclic RGD polypeptide with high affinity for αvβ3, which is capable of disrupting cellular integrin interactions. Cyclo(RGDfC) TFA inhibits pluripotent gene expression in embryonic stem cells (ESCs) and inhibits tumorigenic potential of mESCs in vivo. Cyclo(RGDfC) TFA inhibits the tumorigenic potential of mESC. Cyclo(RGDfC) TFA can be used for tumor-related studies. |
In vitro | 0.5 mM Cyclo(RGDfC) TFA, treated for 24 h was able to down-regulate the expression of the transcription factors Oct 4, Sox 2, and Nanog in mESC and inhibit the expression of integrin genes in the mESC-col I (collagen type I) construct. In addition, treated mESC cells formed agglomerates and detached from the surface. [1] |
In vivo | 0.5 mM Cyclo(RGDfC) TFA, treated for 24 h. Treated mESC in the presence or absence of leukemia inhibitory factor (LIF) (by double leg injection) inhibited teratoma formation in severe combined immunodeficiency (SCID) mice. [1] |
Alias | Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA |
Molecular Weight | 692.67 |
Formula | C26H35F3N8O9S |
Smiles | O=C([C@@H](NC(CNC([C@@H](NC([C@@H](NC1=O)CS)=O)CCCNC(N)=N)=O)=O)CC(O)=O)N[C@@H]1CC2=CC=CC=C2.OC(C(F)(F)F)=O |
Storage | keep away from moisture,keep away from direct sunlight,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | H2O: 10 mg/mL (14.44 mM), Sonication is recommended. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
H2O
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.